A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia

14 January 2021

NatCommun (2020) https://doi.org/10.1038/s41467-020-20560-y

Adrien Flahault, Pierre-Emmanuel Girault-Sotias, Mathilde Keck, Rodrigo Alvear-Perez, Nadia De Mota, Lucie Estéoulle, Sridévi M. Ramanoudjame, Xavier Iturrioz, Dominique Bonnet*, Catherine Llorens-Cortes* 


Thanks to our patented FluoroPEP technology, we developed in collaboration with C. Llorens-Cortes team a metabolically stable fluoroapelin GPCR peptide (LIT01-196) for hyponatremia treatment, especially in the context of the syndrome of inappropriate antidiuresis.